NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
| Autor: | Takeshi Yuasa, Junya Kuroda, Yuri Kamitsuji, Eri Kawata, Kiyoshi Sato, Tomoko Niwa, Shinya Kimura, Asumi Yokota, Hidekazu Segawa, Tetsuo Asaki, Kazuko Hirabayashi, Taira Maekawa, Haruna Naruoka, Yohei Nakaya, Eishi Ashihara, Haruna Naito, Tatsushi Wakayama, Kimio Nasu |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.drug_class
Immunology Genes abl Biology Philadelphia chromosome Biochemistry Piperazines Tyrosine-kinase inhibitor Mice LYN Cell Line Tumor hemic and lymphatic diseases medicine Animals Humans Protein Kinase Inhibitors neoplasms Leukemia ABL Imatinib Cell Biology Hematology medicine.disease Pyrimidines src-Family Kinases Imatinib mesylate Drug Resistance Neoplasm Benzamides Mutation Imatinib Mesylate Cancer research Female Tyrosine kinase Proto-oncogene tyrosine-protein kinase Src medicine.drug |
| Zdroj: | Blood. 106:3948-3954 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2005-06-2209 |
| Popis: | Although the Abelson (Abl) tyrosine kinase inhibitor imatinib mesylate has improved the treatment of breakpoint cluster region–Abl (Bcr-Abl)–positive leukemia, resistance is often reported in patients with advanced-stage disease. Although several Src inhibitors are more effective than imatinib and simultaneously inhibit Lyn, whose overexpression is associated with imatinib resistance, these inhibitors are less specific than imatinib. We have identified a specific dual Abl-Lyn inhibitor, NS-187 (elsewhere described as CNS-9), which is 25 to 55 times more potent than imatinib in vitro. NS-187 is also at least 10 times as effective as imatinib in suppressing the growth of Bcr-Abl–bearing tumors and markedly extends the survival of mice bearing such tumors. The inhibitory effect of NS-187 extends to 12 of 13 Bcr-Abl proteins with mutations in their kinase domain but not to T315I. NS-187 also inhibits Lyn without affecting the phosphorylation of Src, Blk, or Yes. These results suggest that NS-187 may be a potentially valuable novel agent to combat imatinib-resistant Philadelphia-positive (Ph+) leukemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|